RE:RE:Epigenetics GeneralThere are many companies with pan BET inhibitors that are NOT selective for bromodomain-1 vs. bromodomain-2. However, Resverlogix is the ONLY company with a bromodomain-2 selective BET inhibitor, apabetalone (RVX-208). Resverlogix is also the only company with a BET inhibitor in clinical trials for anything other than cancer. In addition to the cardiovascular/diabetes/renal area, we've seen Resverlogix discuss many other distinct diseases in the inflammation, autoimmune, complement area that may also be promising targets for their unique bromodomain-2 selective therapy.
So for Zenith, which is in prostate cancer clinical trials with the ZEN-3694 pan BET inhibitor, the jury is still out as to whether their pan-BET inhibitor has any clinical advantage or lead time over other competitors with pan BET inhibitors in cancer clinical trials.
But for Resverlogix, there are no other companies with bromodomain selective BET inhibitors in clinical trials and no other companies with BET inhibitors in trials for any indication other than cancer. In my opinion, this is where their lead comes from and as long as RVX-208/apabetalone continues to be shown to be safe in long term studies, their lead in the bromodomain-selective BET inhibitor arena will persist.
BearDownAZ